Evidence map›Paper›PMID 26804168›Full record

ArticleOncogene2016

Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.

A N Paranjape, R Soundararajan, S J Werden, R Joseph, J H Taube, H Liu, J Rodriguez-Canales, N Sphyris, I Wistuba, N Miura and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostateFrontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

A N ParanjapeDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
R SoundararajanDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
S J WerdenDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
R JosephDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
J H TaubeDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
H LiuDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
J Rodriguez-CanalesDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
N SphyrisDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
I WistubaDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
N MiuraDepartment of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
J DhillonDepartment of Oncological Sciences, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
N MahajanDepartment of Oncological Sciences, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
K MahajanDepartment of Oncological Sciences, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
J T ChangDepartment of Integrative Biology and Pharmacology, School of Medicine, School of Biomedical Informatics, UT Health Sciences Center at Houston, Houston, TX, USA.
M IttmannDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
S N MaityDepartment of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
C LogothetisDepartment of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
D G TangDepartment of Molecular Carcinogenesis, Science Park, UT MD Anderson Cancer Center, Smithville, TX, USA.
S A ManiDepartment of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of South Florida · USBaylor College of Medicine · USHamamatsu University School of Medicine · JPMoffitt Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progressionR01CA155243 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MANI, SENDURAI AYYAVOO · 2011 to 2022
$3.2M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA155243
6 · The paper itself

Abstract

Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the AR-positive cells within the tumor, eradicating this population eventually leads to castration-resistance, owing to the continued survival of AR

Indexed as

Drug Resistance, NeoplasmAndrogensAnimalsBenzamidesCell Line, TumorDisease Models, AnimalEpithelial-Mesenchymal TransitionEpitheliumForkhead Transcription FactorsGene ExpressionHumansMaleMAP Kinase Signaling SystemMiceModels, BiologicalNeoplasm GradingAndrogensBenzamidesenzalutamideForkhead Transcription Factorsmesenchyme fork head 1 proteinNitrilesPhenylthiohydantoinProstate-Specific AntigenReceptors, AndrogenZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID26804168
PMCPMC5116559
OpenAlexW2268952684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.